Jeffry Keyes Biography and Net Worth

CFO of Quantum-Si

Mr. Keyes brings over 25 years of experience in senior financial positions providing financial leadership for emerging and evolving public and private companies. Previously, he served as the Chief Financial Officer of Spinal Elements, Inc., a private equity backed medical device company. Prior to Spinal Elements, Mr. Keyes was the Chief Financial Officer of Custopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals, where he helped lead the company through rapid commercial growth and successful acquisition by Hikma Pharmaceuticals. Prior to Custopharm, Mr. Keyes held a variety of leadership roles in life science companies in finance, accounting, and mergers and acquisitions support, and he started his career in public accounting. Mr. Keyes has also served on the board of directors of CNS Pharmaceuticals, Inc., a public clinical stage biotech company, since June 2018. Mr. Keyes earned a B.A. degree in accounting from Western Washington University and is a certified public accountant.

What is Jeffry R. Keyes' net worth?: The estimated net worth of Jeffry R. Keyes is at least $1.67 million as of April 21st, 2026. Keyes owns 1,732,582 shares of Quantum-Si stock worth more than $1,670,209 as of May 21st. This net worth evaluation does not reflect any other assets that Keyes may own. Learn More about Jeffry R. Keyes' net worth.
How do I contact Jeffry R. Keyes?: The corporate mailing address for Keyes and other Quantum-Si executives is 452 FIFTH AVENUE 21ST FLOOR, NEW YORK NY, 10018. Quantum-Si can also be reached via phone at 866-688-7374 and via email at [email protected]. Learn More on Jeffry R. Keyes' contact information.
Has Jeffry R. Keyes been buying or selling shares of Quantum-Si?: Over the course of the past ninety days, Jeffry R. Keyes has sold $74,763.01 of Quantum-Si stock. Most recently, Jeffry R. Keyes sold 37,381 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $0.99, for a transaction totalling $37,007.19. Following the completion of the sale, the chief financial officer now directly owns 1,732,582 shares of the company's stock, valued at $1,715,256.18. Learn More on Jeffry R. Keyes' trading history.
Who are Quantum-Si's active insiders?: Quantum-Si's insider roster includes Jeffrey Hawkins (CEO), Jeffry Keyes (CFO), Charles Kummeth (Director), Christian LaPointe (General Counsel), Jonathan Rothberg (Director), John Stark, VIII (CEO), and John Vieceli (Insider). Learn More on Quantum-Si's active insiders.
Are insiders buying or selling shares of Quantum-Si?: In the last year, Quantum-Si insiders bought shares 2 times. They purchased a total of 609,890 shares worth more than $564,395.50. In the last year, insiders at the sold shares 20 times. They sold a total of 390,353 shares worth more than $513,904.91. The most recent insider tranaction occured on April, 21st when CFO Jeffry R Keyes sold 37,381 shares worth more than $37,007.19. Insiders at Quantum-Si own 22.0% of the company. Learn More about insider trades at Quantum-Si.
Information on this page was last updated on 4/21/2026.

Jeffry R. Keyes Insider Trading History at Quantum-Si

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/21/2026	Sell	37,381	$0.99	$37,007.19	1,732,582
4/20/2026	Sell	37,382	$1.01	$37,755.82	1,769,963
3/23/2026	Sell	4,422	$0.83	$3,670.26	1,807,345
3/20/2026	Sell	4,233	$0.85	$3,598.05	1,811,767
12/22/2025	Sell	8,627	$1.28	$11,042.56	1,163,197
9/22/2025	Sell	3,873	$1.68	$6,506.64	1,175,697
6/23/2025	Sell	8,624	$1.61	$13,884.64	1,179,570
3/21/2025	Sell	8,626	$1.39	$11,990.14	1,188,194
8/9/2024	Buy	50,000	$0.87	$43,500.00	446,820
3/5/2024	Buy	50,000	$1.61	$80,500.00	50,000

Jeffry R. Keyes Buying and Selling Activity at Quantum-Si

Quantum-Si Company Overview

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.

Today's Range

Now: $0.97

$0.87

$0.97

50 Day Range

MA: $0.89

$0.71

$1.07

2 Week Range

Now: $0.97

$0.69

$3.10

Volume

8,230,747 shs

Average Volume

4,738,906 shs

Market Capitalization

$211.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.15